img

Global COVID-19 Neutralizing Antibody Drugs Market Insights, Forecast to 2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global COVID-19 Neutralizing Antibody Drugs Market Insights, Forecast to 2034

The main mechanism of action of the COVID-19 neutralizing antibody drugs is to neutralize the new coronavirus and prevent the virus from being adsorbed on susceptible cells, thereby blocking the virus or its genetic material from entering the intracellular proliferation.
Global COVID-19 Neutralizing Antibody Drugs market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, COVID-19 Neutralizing Antibody Drugs industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global COVID-19 Neutralizing Antibody Drugs market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global COVID-19 Neutralizing Antibody Drugs market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Tychan
AstraZeneca
Molecular Partners AG/诺华
Eli Lilly
Regeneron Pharmaceuticals
Abpro
Shanghai Junshi Biosciences
Brii Biosciences
Mabwell Bioscience
Sinocelltech
BeiGene
Segment by Type
ACE2 Fusion Protein
Neutralizing Antibody

Segment by Application


Hospital
Clinic

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ COVID-19 Neutralizing Antibody Drugs plant distribution, commercial date of COVID-19 Neutralizing Antibody Drugs, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, COVID-19 Neutralizing Antibody Drugs introduction, etc. COVID-19 Neutralizing Antibody Drugs Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of COVID-19 Neutralizing Antibody Drugs
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 COVID-19 Neutralizing Antibody Drugs Product Introduction
1.2 Market by Type
1.2.1 Global COVID-19 Neutralizing Antibody Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 ACE2 Fusion Protein
1.2.3 Neutralizing Antibody
1.3 Market by Application
1.3.1 Global COVID-19 Neutralizing Antibody Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global COVID-19 Neutralizing Antibody Drugs Sales Estimates and Forecasts 2018-2029
2.2 Global COVID-19 Neutralizing Antibody Drugs Revenue by Region
2.2.1 Global COVID-19 Neutralizing Antibody Drugs Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global COVID-19 Neutralizing Antibody Drugs Revenue by Region (2018-2024)
2.2.3 Global COVID-19 Neutralizing Antibody Drugs Revenue by Region (2024-2029)
2.2.4 Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Region (2018-2029)
2.3 Global COVID-19 Neutralizing Antibody Drugs Sales Estimates and Forecasts 2018-2029
2.4 Global COVID-19 Neutralizing Antibody Drugs Sales by Region
2.4.1 Global COVID-19 Neutralizing Antibody Drugs Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global COVID-19 Neutralizing Antibody Drugs Sales by Region (2018-2024)
2.4.3 Global COVID-19 Neutralizing Antibody Drugs Sales by Region (2024-2029)
2.4.4 Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global COVID-19 Neutralizing Antibody Drugs Sales by Manufacturers
3.1.1 Global COVID-19 Neutralizing Antibody Drugs Sales by Manufacturers (2018-2024)
3.1.2 Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of COVID-19 Neutralizing Antibody Drugs in 2022
3.2 Global COVID-19 Neutralizing Antibody Drugs Revenue by Manufacturers
3.2.1 Global COVID-19 Neutralizing Antibody Drugs Revenue by Manufacturers (2018-2024)
3.2.2 Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by COVID-19 Neutralizing Antibody Drugs Revenue in 2022
3.3 Global Key Players of COVID-19 Neutralizing Antibody Drugs, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global COVID-19 Neutralizing Antibody Drugs Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global COVID-19 Neutralizing Antibody Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of COVID-19 Neutralizing Antibody Drugs, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of COVID-19 Neutralizing Antibody Drugs, Product Offered and Application
3.8 Global Key Manufacturers of COVID-19 Neutralizing Antibody Drugs, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global COVID-19 Neutralizing Antibody Drugs Sales by Type
4.1.1 Global COVID-19 Neutralizing Antibody Drugs Historical Sales by Type (2018-2024)
4.1.2 Global COVID-19 Neutralizing Antibody Drugs Forecasted Sales by Type (2024-2029)
4.1.3 Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Type (2018-2029)
4.2 Global COVID-19 Neutralizing Antibody Drugs Revenue by Type
4.2.1 Global COVID-19 Neutralizing Antibody Drugs Historical Revenue by Type (2018-2024)
4.2.2 Global COVID-19 Neutralizing Antibody Drugs Forecasted Revenue by Type (2024-2029)
4.2.3 Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Type (2018-2029)
4.3 Global COVID-19 Neutralizing Antibody Drugs Price by Type
4.3.1 Global COVID-19 Neutralizing Antibody Drugs Price by Type (2018-2024)
4.3.2 Global COVID-19 Neutralizing Antibody Drugs Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global COVID-19 Neutralizing Antibody Drugs Sales by Application
5.1.1 Global COVID-19 Neutralizing Antibody Drugs Historical Sales by Application (2018-2024)
5.1.2 Global COVID-19 Neutralizing Antibody Drugs Forecasted Sales by Application (2024-2029)
5.1.3 Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Application (2018-2029)
5.2 Global COVID-19 Neutralizing Antibody Drugs Revenue by Application
5.2.1 Global COVID-19 Neutralizing Antibody Drugs Historical Revenue by Application (2018-2024)
5.2.2 Global COVID-19 Neutralizing Antibody Drugs Forecasted Revenue by Application (2024-2029)
5.2.3 Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Application (2018-2029)
5.3 Global COVID-19 Neutralizing Antibody Drugs Price by Application
5.3.1 Global COVID-19 Neutralizing Antibody Drugs Price by Application (2018-2024)
5.3.2 Global COVID-19 Neutralizing Antibody Drugs Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada COVID-19 Neutralizing Antibody Drugs Market Size by Type
6.1.1 US & Canada COVID-19 Neutralizing Antibody Drugs Sales by Type (2018-2029)
6.1.2 US & Canada COVID-19 Neutralizing Antibody Drugs Revenue by Type (2018-2029)
6.2 US & Canada COVID-19 Neutralizing Antibody Drugs Market Size by Application
6.2.1 US & Canada COVID-19 Neutralizing Antibody Drugs Sales by Application (2018-2029)
6.2.2 US & Canada COVID-19 Neutralizing Antibody Drugs Revenue by Application (2018-2029)
6.3 US & Canada COVID-19 Neutralizing Antibody Drugs Market Size by Country
6.3.1 US & Canada COVID-19 Neutralizing Antibody Drugs Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada COVID-19 Neutralizing Antibody Drugs Sales by Country (2018-2029)
6.3.3 US & Canada COVID-19 Neutralizing Antibody Drugs Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe COVID-19 Neutralizing Antibody Drugs Market Size by Type
7.1.1 Europe COVID-19 Neutralizing Antibody Drugs Sales by Type (2018-2029)
7.1.2 Europe COVID-19 Neutralizing Antibody Drugs Revenue by Type (2018-2029)
7.2 Europe COVID-19 Neutralizing Antibody Drugs Market Size by Application
7.2.1 Europe COVID-19 Neutralizing Antibody Drugs Sales by Application (2018-2029)
7.2.2 Europe COVID-19 Neutralizing Antibody Drugs Revenue by Application (2018-2029)
7.3 Europe COVID-19 Neutralizing Antibody Drugs Market Size by Country
7.3.1 Europe COVID-19 Neutralizing Antibody Drugs Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe COVID-19 Neutralizing Antibody Drugs Sales by Country (2018-2029)
7.3.3 Europe COVID-19 Neutralizing Antibody Drugs Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China COVID-19 Neutralizing Antibody Drugs Market Size
8.1.1 China COVID-19 Neutralizing Antibody Drugs Sales (2018-2029)
8.1.2 China COVID-19 Neutralizing Antibody Drugs Revenue (2018-2029)
8.2 China COVID-19 Neutralizing Antibody Drugs Market Size by Application
8.2.1 China COVID-19 Neutralizing Antibody Drugs Sales by Application (2018-2029)
8.2.2 China COVID-19 Neutralizing Antibody Drugs Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia COVID-19 Neutralizing Antibody Drugs Market Size by Type
9.1.1 Asia COVID-19 Neutralizing Antibody Drugs Sales by Type (2018-2029)
9.1.2 Asia COVID-19 Neutralizing Antibody Drugs Revenue by Type (2018-2029)
9.2 Asia COVID-19 Neutralizing Antibody Drugs Market Size by Application
9.2.1 Asia COVID-19 Neutralizing Antibody Drugs Sales by Application (2018-2029)
9.2.2 Asia COVID-19 Neutralizing Antibody Drugs Revenue by Application (2018-2029)
9.3 Asia COVID-19 Neutralizing Antibody Drugs Sales by Region
9.3.1 Asia COVID-19 Neutralizing Antibody Drugs Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia COVID-19 Neutralizing Antibody Drugs Revenue by Region (2018-2029)
9.3.3 Asia COVID-19 Neutralizing Antibody Drugs Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Market Size by Type
10.1.1 Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Market Size by Application
10.2.1 Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Sales by Country
10.3.1 Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Tychan
11.1.1 Tychan Company Information
11.1.2 Tychan Overview
11.1.3 Tychan COVID-19 Neutralizing Antibody Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Tychan COVID-19 Neutralizing Antibody Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Tychan Recent Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Company Information
11.2.2 AstraZeneca Overview
11.2.3 AstraZeneca COVID-19 Neutralizing Antibody Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 AstraZeneca COVID-19 Neutralizing Antibody Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 AstraZeneca Recent Developments
11.3 Molecular Partners AG/诺华
11.3.1 Molecular Partners AG/诺华 Company Information
11.3.2 Molecular Partners AG/诺华 Overview
11.3.3 Molecular Partners AG/诺华 COVID-19 Neutralizing Antibody Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Molecular Partners AG/诺华 COVID-19 Neutralizing Antibody Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Molecular Partners AG/诺华 Recent Developments
11.4 Eli Lilly
11.4.1 Eli Lilly Company Information
11.4.2 Eli Lilly Overview
11.4.3 Eli Lilly COVID-19 Neutralizing Antibody Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Eli Lilly COVID-19 Neutralizing Antibody Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Eli Lilly Recent Developments
11.5 Regeneron Pharmaceuticals
11.5.1 Regeneron Pharmaceuticals Company Information
11.5.2 Regeneron Pharmaceuticals Overview
11.5.3 Regeneron Pharmaceuticals COVID-19 Neutralizing Antibody Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Regeneron Pharmaceuticals COVID-19 Neutralizing Antibody Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Regeneron Pharmaceuticals Recent Developments
11.6 Abpro
11.6.1 Abpro Company Information
11.6.2 Abpro Overview
11.6.3 Abpro COVID-19 Neutralizing Antibody Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Abpro COVID-19 Neutralizing Antibody Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Abpro Recent Developments
11.7 Shanghai Junshi Biosciences
11.7.1 Shanghai Junshi Biosciences Company Information
11.7.2 Shanghai Junshi Biosciences Overview
11.7.3 Shanghai Junshi Biosciences COVID-19 Neutralizing Antibody Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Shanghai Junshi Biosciences COVID-19 Neutralizing Antibody Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Shanghai Junshi Biosciences Recent Developments
11.8 Brii Biosciences
11.8.1 Brii Biosciences Company Information
11.8.2 Brii Biosciences Overview
11.8.3 Brii Biosciences COVID-19 Neutralizing Antibody Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 Brii Biosciences COVID-19 Neutralizing Antibody Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Brii Biosciences Recent Developments
11.9 Mabwell Bioscience
11.9.1 Mabwell Bioscience Company Information
11.9.2 Mabwell Bioscience Overview
11.9.3 Mabwell Bioscience COVID-19 Neutralizing Antibody Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 Mabwell Bioscience COVID-19 Neutralizing Antibody Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Mabwell Bioscience Recent Developments
11.10 Sinocelltech
11.10.1 Sinocelltech Company Information
11.10.2 Sinocelltech Overview
11.10.3 Sinocelltech COVID-19 Neutralizing Antibody Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 Sinocelltech COVID-19 Neutralizing Antibody Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Sinocelltech Recent Developments
11.11 BeiGene
11.11.1 BeiGene Company Information
11.11.2 BeiGene Overview
11.11.3 BeiGene COVID-19 Neutralizing Antibody Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.11.4 BeiGene COVID-19 Neutralizing Antibody Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 BeiGene Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 COVID-19 Neutralizing Antibody Drugs Industry Chain Analysis
12.2 COVID-19 Neutralizing Antibody Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 COVID-19 Neutralizing Antibody Drugs Production Mode & Process
12.4 COVID-19 Neutralizing Antibody Drugs Sales and Marketing
12.4.1 COVID-19 Neutralizing Antibody Drugs Sales Channels
12.4.2 COVID-19 Neutralizing Antibody Drugs Distributors
12.5 COVID-19 Neutralizing Antibody Drugs Customers
13 Market Dynamics
13.1 COVID-19 Neutralizing Antibody Drugs Industry Trends
13.2 COVID-19 Neutralizing Antibody Drugs Market Drivers
13.3 COVID-19 Neutralizing Antibody Drugs Market Challenges
13.4 COVID-19 Neutralizing Antibody Drugs Market Restraints
14 Key Findings in The Global COVID-19 Neutralizing Antibody Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global COVID-19 Neutralizing Antibody Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of ACE2 Fusion Protein
Table 3. Major Manufacturers of Neutralizing Antibody
Table 4. Global COVID-19 Neutralizing Antibody Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 5. Global COVID-19 Neutralizing Antibody Drugs Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global COVID-19 Neutralizing Antibody Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global COVID-19 Neutralizing Antibody Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 8. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Region (2018-2024)
Table 9. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Region (2024-2029)
Table 10. Global COVID-19 Neutralizing Antibody Drugs Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 11. Global COVID-19 Neutralizing Antibody Drugs Sales by Region (2018-2024) & (K Units)
Table 12. Global COVID-19 Neutralizing Antibody Drugs Sales by Region (2024-2029) & (K Units)
Table 13. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Region (2018-2024)
Table 14. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Region (2024-2029)
Table 15. Global COVID-19 Neutralizing Antibody Drugs Sales by Manufacturers (2018-2024) & (K Units)
Table 16. Global COVID-19 Neutralizing Antibody Drugs Sales Share by Manufacturers (2018-2024)
Table 17. Global COVID-19 Neutralizing Antibody Drugs Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global COVID-19 Neutralizing Antibody Drugs Revenue Share by Manufacturers (2018-2024)
Table 19. Global Key Players of COVID-19 Neutralizing Antibody Drugs, Industry Ranking, 2021 VS 2022 VS 2024
Table 20. COVID-19 Neutralizing Antibody Drugs Price by Manufacturers 2018-2024 (US$/Unit)
Table 21. Global COVID-19 Neutralizing Antibody Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global COVID-19 Neutralizing Antibody Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in COVID-19 Neutralizing Antibody Drugs as of 2022)
Table 23. Global Key Manufacturers of COVID-19 Neutralizing Antibody Drugs, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of COVID-19 Neutralizing Antibody Drugs, Product Offered and Application
Table 25. Global Key Manufacturers of COVID-19 Neutralizing Antibody Drugs, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global COVID-19 Neutralizing Antibody Drugs Sales by Type (2018-2024) & (K Units)
Table 28. Global COVID-19 Neutralizing Antibody Drugs Sales by Type (2024-2029) & (K Units)
Table 29. Global COVID-19 Neutralizing Antibody Drugs Sales Share by Type (2018-2024)
Table 30. Global COVID-19 Neutralizing Antibody Drugs Sales Share by Type (2024-2029)
Table 31. Global COVID-19 Neutralizing Antibody Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global COVID-19 Neutralizing Antibody Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 33. Global COVID-19 Neutralizing Antibody Drugs Revenue Share by Type (2018-2024)
Table 34. Global COVID-19 Neutralizing Antibody Drugs Revenue Share by Type (2024-2029)
Table 35. COVID-19 Neutralizing Antibody Drugs Price by Type (2018-2024) & (US$/Unit)
Table 36. Global COVID-19 Neutralizing Antibody Drugs Price Forecast by Type (2024-2029) & (US$/Unit)
Table 37. Global COVID-19 Neutralizing Antibody Drugs Sales by Application (2018-2024) & (K Units)
Table 38. Global COVID-19 Neutralizing Antibody Drugs Sales by Application (2024-2029) & (K Units)
Table 39. Global COVID-19 Neutralizing Antibody Drugs Sales Share by Application (2018-2024)
Table 40. Global COVID-19 Neutralizing Antibody Drugs Sales Share by Application (2024-2029)
Table 41. Global COVID-19 Neutralizing Antibody Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global COVID-19 Neutralizing Antibody Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 43. Global COVID-19 Neutralizing Antibody Drugs Revenue Share by Application (2018-2024)
Table 44. Global COVID-19 Neutralizing Antibody Drugs Revenue Share by Application (2024-2029)
Table 45. COVID-19 Neutralizing Antibody Drugs Price by Application (2018-2024) & (US$/Unit)
Table 46. Global COVID-19 Neutralizing Antibody Drugs Price Forecast by Application (2024-2029) & (US$/Unit)
Table 47. US & Canada COVID-19 Neutralizing Antibody Drugs Sales by Type (2018-2024) & (K Units)
Table 48. US & Canada COVID-19 Neutralizing Antibody Drugs Sales by Type (2024-2029) & (K Units)
Table 49. US & Canada COVID-19 Neutralizing Antibody Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 50. US & Canada COVID-19 Neutralizing Antibody Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 51. US & Canada COVID-19 Neutralizing Antibody Drugs Sales by Application (2018-2024) & (K Units)
Table 52. US & Canada COVID-19 Neutralizing Antibody Drugs Sales by Application (2024-2029) & (K Units)
Table 53. US & Canada COVID-19 Neutralizing Antibody Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 54. US & Canada COVID-19 Neutralizing Antibody Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 55. US & Canada COVID-19 Neutralizing Antibody Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 56. US & Canada COVID-19 Neutralizing Antibody Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 57. US & Canada COVID-19 Neutralizing Antibody Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 58. US & Canada COVID-19 Neutralizing Antibody Drugs Sales by Country (2018-2024) & (K Units)
Table 59. US & Canada COVID-19 Neutralizing Antibody Drugs Sales by Country (2024-2029) & (K Units)
Table 60. Europe COVID-19 Neutralizing Antibody Drugs Sales by Type (2018-2024) & (K Units)
Table 61. Europe COVID-19 Neutralizing Antibody Drugs Sales by Type (2024-2029) & (K Units)
Table 62. Europe COVID-19 Neutralizing Antibody Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 63. Europe COVID-19 Neutralizing Antibody Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 64. Europe COVID-19 Neutralizing Antibody Drugs Sales by Application (2018-2024) & (K Units)
Table 65. Europe COVID-19 Neutralizing Antibody Drugs Sales by Application (2024-2029) & (K Units)
Table 66. Europe COVID-19 Neutralizing Antibody Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 67. Europe COVID-19 Neutralizing Antibody Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 68. Europe COVID-19 Neutralizing Antibody Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 69. Europe COVID-19 Neutralizing Antibody Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 70. Europe COVID-19 Neutralizing Antibody Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 71. Europe COVID-19 Neutralizing Antibody Drugs Sales by Country (2018-2024) & (K Units)
Table 72. Europe COVID-19 Neutralizing Antibody Drugs Sales by Country (2024-2029) & (K Units)
Table 73. China COVID-19 Neutralizing Antibody Drugs Sales by Type (2018-2024) & (K Units)
Table 74. China COVID-19 Neutralizing Antibody Drugs Sales by Type (2024-2029) & (K Units)
Table 75. China COVID-19 Neutralizing Antibody Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 76. China COVID-19 Neutralizing Antibody Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 77. China COVID-19 Neutralizing Antibody Drugs Sales by Application (2018-2024) & (K Units)
Table 78. China COVID-19 Neutralizing Antibody Drugs Sales by Application (2024-2029) & (K Units)
Table 79. China COVID-19 Neutralizing Antibody Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 80. China COVID-19 Neutralizing Antibody Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 81. Asia COVID-19 Neutralizing Antibody Drugs Sales by Type (2018-2024) & (K Units)
Table 82. Asia COVID-19 Neutralizing Antibody Drugs Sales by Type (2024-2029) & (K Units)
Table 83. Asia COVID-19 Neutralizing Antibody Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 84. Asia COVID-19 Neutralizing Antibody Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 85. Asia COVID-19 Neutralizing Antibody Drugs Sales by Application (2018-2024) & (K Units)
Table 86. Asia COVID-19 Neutralizing Antibody Drugs Sales by Application (2024-2029) & (K Units)
Table 87. Asia COVID-19 Neutralizing Antibody Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 88. Asia COVID-19 Neutralizing Antibody Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 89. Asia COVID-19 Neutralizing Antibody Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 90. Asia COVID-19 Neutralizing Antibody Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 91. Asia COVID-19 Neutralizing Antibody Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 92. Asia COVID-19 Neutralizing Antibody Drugs Sales by Region (2018-2024) & (K Units)
Table 93. Asia COVID-19 Neutralizing Antibody Drugs Sales by Region (2024-2029) & (K Units)
Table 94. Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Sales by Type (2018-2024) & (K Units)
Table 95. Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Sales by Type (2024-2029) & (K Units)
Table 96. Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 97. Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 98. Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Sales by Application (2018-2024) & (K Units)
Table 99. Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Sales by Application (2024-2029) & (K Units)
Table 100. Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 101. Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 102. Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 103. Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 105. Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Sales by Country (2018-2024) & (K Units)
Table 106. Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Sales by Country (2024-2029) & (K Units)
Table 107. Tychan Company Information
Table 108. Tychan Description and Major Businesses
Table 109. Tychan COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 110. Tychan COVID-19 Neutralizing Antibody Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Tychan Recent Developments
Table 112. AstraZeneca Company Information
Table 113. AstraZeneca Description and Major Businesses
Table 114. AstraZeneca COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 115. AstraZeneca COVID-19 Neutralizing Antibody Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. AstraZeneca Recent Developments
Table 117. Molecular Partners AG/诺华 Company Information
Table 118. Molecular Partners AG/诺华 Description and Major Businesses
Table 119. Molecular Partners AG/诺华 COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 120. Molecular Partners AG/诺华 COVID-19 Neutralizing Antibody Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Molecular Partners AG/诺华 Recent Developments
Table 122. Eli Lilly Company Information
Table 123. Eli Lilly Description and Major Businesses
Table 124. Eli Lilly COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 125. Eli Lilly COVID-19 Neutralizing Antibody Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Eli Lilly Recent Developments
Table 127. Regeneron Pharmaceuticals Company Information
Table 128. Regeneron Pharmaceuticals Description and Major Businesses
Table 129. Regeneron Pharmaceuticals COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 130. Regeneron Pharmaceuticals COVID-19 Neutralizing Antibody Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Regeneron Pharmaceuticals Recent Developments
Table 132. Abpro Company Information
Table 133. Abpro Description and Major Businesses
Table 134. Abpro COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 135. Abpro COVID-19 Neutralizing Antibody Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Abpro Recent Developments
Table 137. Shanghai Junshi Biosciences Company Information
Table 138. Shanghai Junshi Biosciences Description and Major Businesses
Table 139. Shanghai Junshi Biosciences COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 140. Shanghai Junshi Biosciences COVID-19 Neutralizing Antibody Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Shanghai Junshi Biosciences Recent Developments
Table 142. Brii Biosciences Company Information
Table 143. Brii Biosciences Description and Major Businesses
Table 144. Brii Biosciences COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 145. Brii Biosciences COVID-19 Neutralizing Antibody Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Brii Biosciences Recent Developments
Table 147. Mabwell Bioscience Company Information
Table 148. Mabwell Bioscience Description and Major Businesses
Table 149. Mabwell Bioscience COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 150. Mabwell Bioscience COVID-19 Neutralizing Antibody Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Mabwell Bioscience Recent Developments
Table 152. Sinocelltech Company Information
Table 153. Sinocelltech Description and Major Businesses
Table 154. Sinocelltech COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 155. Sinocelltech COVID-19 Neutralizing Antibody Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Sinocelltech Recent Developments
Table 157. BeiGene Company Information
Table 158. BeiGene Description and Major Businesses
Table 159. BeiGene COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 160. BeiGene COVID-19 Neutralizing Antibody Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. BeiGene Recent Developments
Table 162. Key Raw Materials Lists
Table 163. Raw Materials Key Suppliers Lists
Table 164. COVID-19 Neutralizing Antibody Drugs Distributors List
Table 165. COVID-19 Neutralizing Antibody Drugs Customers List
Table 166. COVID-19 Neutralizing Antibody Drugs Market Trends
Table 167. COVID-19 Neutralizing Antibody Drugs Market Drivers
Table 168. COVID-19 Neutralizing Antibody Drugs Market Challenges
Table 169. COVID-19 Neutralizing Antibody Drugs Market Restraints
Table 170. Research Programs/Design for This Report
Table 171. Key Data Information from Secondary Sources
Table 172. Key Data Information from Primary Sources
List of Figures
Figure 1. COVID-19 Neutralizing Antibody Drugs Product Picture
Figure 2. Global COVID-19 Neutralizing Antibody Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global COVID-19 Neutralizing Antibody Drugs Market Share by Type in 2022 & 2029
Figure 4. ACE2 Fusion Protein Product Picture
Figure 5. Neutralizing Antibody Product Picture
Figure 6. Global COVID-19 Neutralizing Antibody Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 7. Global COVID-19 Neutralizing Antibody Drugs Market Share by Application in 2022 & 2029
Figure 8. Hospital
Figure 9. Clinic
Figure 10. COVID-19 Neutralizing Antibody Drugs Report Years Considered
Figure 11. Global COVID-19 Neutralizing Antibody Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 12. Global COVID-19 Neutralizing Antibody Drugs Revenue 2018-2029 (US$ Million)
Figure 13. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 14. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Region (2018-2029)
Figure 15. Global COVID-19 Neutralizing Antibody Drugs Sales 2018-2029 ((K Units)
Figure 16. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Region (2018-2029)
Figure 17. US & Canada COVID-19 Neutralizing Antibody Drugs Sales YoY (2018-2029) & (K Units)
Figure 18. US & Canada COVID-19 Neutralizing Antibody Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 19. Europe COVID-19 Neutralizing Antibody Drugs Sales YoY (2018-2029) & (K Units)
Figure 20. Europe COVID-19 Neutralizing Antibody Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 21. China COVID-19 Neutralizing Antibody Drugs Sales YoY (2018-2029) & (K Units)
Figure 22. China COVID-19 Neutralizing Antibody Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 23. Asia (excluding China) COVID-19 Neutralizing Antibody Drugs Sales YoY (2018-2029) & (K Units)
Figure 24. Asia (excluding China) COVID-19 Neutralizing Antibody Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 25. Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Sales YoY (2018-2029) & (K Units)
Figure 26. Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 27. The COVID-19 Neutralizing Antibody Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 28. The Top 5 and 10 Largest Manufacturers of COVID-19 Neutralizing Antibody Drugs in the World: Market Share by COVID-19 Neutralizing Antibody Drugs Revenue in 2022
Figure 29. Global COVID-19 Neutralizing Antibody Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 30. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Type (2018-2029)
Figure 31. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Type (2018-2029)
Figure 32. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Application (2018-2029)
Figure 33. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Application (2018-2029)
Figure 34. US & Canada COVID-19 Neutralizing Antibody Drugs Sales Market Share by Type (2018-2029)
Figure 35. US & Canada COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Type (2018-2029)
Figure 36. US & Canada COVID-19 Neutralizing Antibody Drugs Sales Market Share by Application (2018-2029)
Figure 37. US & Canada COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Application (2018-2029)
Figure 38. US & Canada COVID-19 Neutralizing Antibody Drugs Revenue Share by Country (2018-2029)
Figure 39. US & Canada COVID-19 Neutralizing Antibody Drugs Sales Share by Country (2018-2029)
Figure 40. U.S. COVID-19 Neutralizing Antibody Drugs Revenue (2018-2029) & (US$ Million)
Figure 41. Canada COVID-19 Neutralizing Antibody Drugs Revenue (2018-2029) & (US$ Million)
Figure 42. Europe COVID-19 Neutralizing Antibody Drugs Sales Market Share by Type (2018-2029)
Figure 43. Europe COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Type (2018-2029)
Figure 44. Europe COVID-19 Neutralizing Antibody Drugs Sales Market Share by Application (2018-2029)
Figure 45. Europe COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Application (2018-2029)
Figure 46. Europe COVID-19 Neutralizing Antibody Drugs Revenue Share by Country (2018-2029)
Figure 47. Europe COVID-19 Neutralizing Antibody Drugs Sales Share by Country (2018-2029)
Figure 48. Germany COVID-19 Neutralizing Antibody Drugs Revenue (2018-2029) & (US$ Million)
Figure 49. France COVID-19 Neutralizing Antibody Drugs Revenue (2018-2029) & (US$ Million)
Figure 50. U.K. COVID-19 Neutralizing Antibody Drugs Revenue (2018-2029) & (US$ Million)
Figure 51. Italy COVID-19 Neutralizing Antibody Drugs Revenue (2018-2029) & (US$ Million)
Figure 52. Russia COVID-19 Neutralizing Antibody Drugs Revenue (2018-2029) & (US$ Million)
Figure 53. China COVID-19 Neutralizing Antibody Drugs Sales Market Share by Type (2018-2029)
Figure 54. China COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Type (2018-2029)
Figure 55. China COVID-19 Neutralizing Antibody Drugs Sales Market Share by Application (2018-2029)
Figure 56. China COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Application (2018-2029)
Figure 57. Asia COVID-19 Neutralizing Antibody Drugs Sales Market Share by Type (2018-2029)
Figure 58. Asia COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Type (2018-2029)
Figure 59. Asia COVID-19 Neutralizing Antibody Drugs Sales Market Share by Application (2018-2029)
Figure 60. Asia COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Application (2018-2029)
Figure 61. Asia COVID-19 Neutralizing Antibody Drugs Revenue Share by Region (2018-2029)
Figure 62. Asia COVID-19 Neutralizing Antibody Drugs Sales Share by Region (2018-2029)
Figure 63. Japan COVID-19 Neutralizing Antibody Drugs Revenue (2018-2029) & (US$ Million)
Figure 64. South Korea COVID-19 Neutralizing Antibody Drugs Revenue (2018-2029) & (US$ Million)
Figure 65. China Taiwan COVID-19 Neutralizing Antibody Drugs Revenue (2018-2029) & (US$ Million)
Figure 66. Southeast Asia COVID-19 Neutralizing Antibody Drugs Revenue (2018-2029) & (US$ Million)
Figure 67. India COVID-19 Neutralizing Antibody Drugs Revenue (2018-2029) & (US$ Million)
Figure 68. Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Sales Market Share by Type (2018-2029)
Figure 69. Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Type (2018-2029)
Figure 70. Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Sales Market Share by Application (2018-2029)
Figure 71. Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Application (2018-2029)
Figure 72. Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Revenue Share by Country (2018-2029)
Figure 73. Middle East, Africa and Latin America COVID-19 Neutralizing Antibody Drugs Sales Share by Country (2018-2029)
Figure 74. Brazil COVID-19 Neutralizing Antibody Drugs Revenue (2018-2029) & (US$ Million)
Figure 75. Mexico COVID-19 Neutralizing Antibody Drugs Revenue (2018-2029) & (US$ Million)
Figure 76. Turkey COVID-19 Neutralizing Antibody Drugs Revenue (2018-2029) & (US$ Million)
Figure 77. Israel COVID-19 Neutralizing Antibody Drugs Revenue (2018-2029) & (US$ Million)
Figure 78. GCC Countries COVID-19 Neutralizing Antibody Drugs Revenue (2018-2029) & (US$ Million)
Figure 79. COVID-19 Neutralizing Antibody Drugs Value Chain
Figure 80. COVID-19 Neutralizing Antibody Drugs Production Process
Figure 81. Channels of Distribution
Figure 82. Distributors Profiles
Figure 83. Bottom-up and Top-down Approaches for This Report
Figure 84. Data Triangulation
Figure 85. Key Executives Interviewed